Home › Funds › Elmind Capital, LP › BCRX
Elmind Capital, LP position in BCRX
BIOCRYST PHARMACEUTICALS INC · Health Care
Elmind Capital, LP reported holding 520,000 shares of BCRX (BIOCRYST PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$5.2M, representing 1.31% of its reported portfolio and ranking #19 among its reported holdings. Elmind Capital, LP has disclosed BCRX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Elmind Capital, LP's BCRX position evolved
Elmind Capital, LP first disclosed a stake in BCRX in Q4 2025 at 2,150,000 shares (US$16.8M). Across 3 filings, Elmind Capital, LP increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 520,000 shares valued at US$5.2M — a reduction of -480,000 shares quarter over quarter.. Notable position changes include a 53% trim in Q1 2026 (shares rose 5% over the following quarter), a 48% trim in Q2 2026 (shares fell 17% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 2.15M | $16.77M | New |
| Q1 2026 | 1.00M | $9.52M | Reduce |
| Q2 2026 | 520.00K | $5.20M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BCRX and 13F data
BCRX (BIOCRYST PHARMACEUTICALS INC) is a Health Care company. 47 other funds we track also report a position in BCRX — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$158.3M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$151.0M), TCG Crossover Management, LLC (US$110.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BCRX
- RA CAPITAL MANAGEMENT, L.P. 15.83M sh · $158.27M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 15.10M sh · $150.96M · Q2 2026
- TCG Crossover Management, LLC 11.02M sh · $110.21M · Q2 2026
- PERCEPTIVE ADVISORS LLC 10.31M sh · $103.09M · Q2 2026
- Vestal Point Capital, LP 8.30M sh · $83.00M · Q2 2026
- Frazier Life Sciences Management, L.P. 4.01M sh · $40.09M · Q2 2026
- Kynam Capital Management, LP 2.52M sh · $25.23M · Q2 2026
- RICE HALL JAMES & ASSOCIATES, LLC 2.33M sh · $23.32M · Q2 2026
- Nantahala Capital Management, LLC 1.90M sh · $19.01M · Q2 2026
- Eversept Partners, LP 1.87M sh · $18.66M · Q2 2026
- Parkman Healthcare Partners LLC 1.62M sh · $16.24M · Q2 2026
More on Elmind Capital, LP
FAQ
How long has Elmind Capital, LP held BCRX?
Elmind Capital, LP has disclosed BCRX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Elmind Capital, LP's current position in BCRX?
As of Q2 2026, Elmind Capital, LP holds 520.00K shares of BCRX (BIOCRYST PHARMACEUTICALS INC), valued at $5.20M, representing 1.31% of its reported portfolio and ranking #19.
Has Elmind Capital, LP been buying or selling BCRX?
In the latest 13F filing (Q2 2026), Elmind Capital, LP reduced its position in BCRX.
Which other funds hold BCRX?
Other major institutional holders of BCRX include RA CAPITAL MANAGEMENT, L.P., DEERFIELD MANAGEMENT COMPANY, L.P., TCG Crossover Management, LLC, among 47 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.